Spots Global Cancer Trial Database for HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer

Official Title: A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer

Study ID: NCT02464137

Conditions

Squamous Cell Carcinoma of the Larynx

Interventions

radiation

Study Description

Brief Summary: single-modality phase I dose escalation toxicity study for first-line curative treatment of head and neck squamous cell carcinoma.

Detailed Description: HYDRA will consist of 5 fraction SBRT treatment targeting only grossly evident disease localized by examination and standard diagnostic CT, MR, and PET-CT imaging. Prophylactic coverage of uninvolved at-risk mucosal and nodal drainage basins will be strictly disallowed. The initial dose cohort will be treated to a total of 42.5 Gy in five equal fractions delivered every other day over a two week period (biologically equivalent to 66 Gy delivered in 2 Gy daily fractions), drawn from our successful institutional experience with similar dosing and fractionation for early-stage larynx SBRT. Escalation of total dose will proceed in 2.5 Gy increments, up to a final target dose of 50 Gy.